Read the website of almost any early-stage biotech company and you'll find some version of the same thing: a mechanism of action explained in detail, a pipeline table, and a mission statement about "transforming the treatment of" something. All technically accurate. None of it written for the person who needs to fund, partner with, or buy from the company.
This is the "too science-y" problem. And it's not a writing problem — it's a translation problem.
The people who built the company are scientists. They communicate in the language of science because that's the language their work lives in. When they write about what the company does, they write for an audience of peers. But the people they actually need to reach — investors, commercial partners, KOLs, future customers — need a different kind of explanation. Not dumbed down. Translated.
"Investors don't fund mechanisms. They fund outcomes. Those are different conversations."
A Series A investor asking "what does your company do" wants to know the market problem, the size of the opportunity, and why this particular approach wins. A potential commercial partner wants to know what changes for their patients or customers if they work with you. Neither of them needs to understand the binding kinetics.
The fix isn't to hire a medical writer. Medical writers optimize for accuracy and regulatory compliance. What you need is someone who can read your white papers, patents, and clinical data — and translate it into language that moves people who aren't scientists toward a decision.
That's a commercial skill, not a scientific one. And most life science companies don't build it until they're forced to by a board that wants to see market traction.
Build it earlier. The science doesn't get less impressive when it's explained in plain English. It gets more fundable.
This is exactly what the Science-to-Social Vault fixes.
We take your technical docs and build a full year of commercial content in two weeks.